Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

n -Butylidenephthalide Modulates Autophagy to Ameliorate Neuropathological Progress of Spinocerebellar Ataxia Type 3 through mTOR Pathway

Lee JH., Lin SY., Liu JW., Lin SZ., Harn HJ., Chiou TW.

Animal Study on Neuroinflammation, published in Int J Mol Sci (2021) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Int J Mol Sci (2021)
Reported sample size
—
Source database
Europe PMC
PMID
34199295
PMCID
PMC8231882
DOI
10.3390/ijms22126339
Citations
22

Abstract (original English)

Spinocerebellar ataxia type 3 (SCA3), a hereditary and lethal neurodegenerative disease, is attributed to the abnormal accumulation of undegradable polyglutamine (polyQ), which is encoded by mutated ataxin-3 gene ( ATXN3 ). The toxic fragments processed from mutant ATXN3 can induce neuronal death, leading to the muscular incoordination of the human body. Some treatment strategies of SCA3 are preferentially focused on depleting the abnormal aggregates, which led to the discovery of small molecule n -butylidenephthalide ( n -BP). n -BP-promoted autophagy protected the loss of Purkinje cell in the cerebellum that regulates the network associated with motor functions. We report that the n -BP treatment may be effective in treating SCA3 disease. n -BP treatment led to the depletion of mutant ATXN3 with the expanded polyQ chain and the toxic fragments resulting in increased metabolic activity and alleviated atrophy of SCA3 murine cerebellum. Furthermore, n -BP treated animal and HEK-293 GFP-ATXN3-84Q cell models could consistently show the depletion of aggregates through mTOR inhibition. With its unique mechanism, the two autophagic inhibitors Bafilomycin A1 and wortmannin could halt the n -BP-induced elimination of aggregates. Collectively, n -BP shows promising results for the treatment of SCA3.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
CerebellumPurkinje CellsAnimalsMice, Inbred C57BLHumansMiceMachado-Joseph DiseasePhthalic AnhydridesAdenylate KinaseMotor Activity

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research